Development
Silo Pharma, Inc.
SILO
$0.6293
$0.0315.18%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | 0.00% | 1.12% | -4.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 0.00% | 0.00% | 1.12% | -4.38% |
| Cost of Revenue | 0.00% | 0.00% | 0.00% | 17.65% | 66.67% |
| Gross Profit | 0.00% | 0.00% | 0.00% | 0.00% | 33.33% |
| SG&A Expenses | 76.79% | 90.86% | 56.27% | 3.38% | -15.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.13% | 81.74% | 57.91% | 22.60% | 21.87% |
| Operating Income | -49.32% | -84.15% | -59.63% | -23.14% | -21.58% |
| Income Before Tax | -28.50% | -209.40% | -194.78% | -193.43% | -171.18% |
| Income Tax Expenses | -- | -- | -- | -- | -70.16% |
| Earnings from Continuing Operations | -28.27% | -210.05% | -195.31% | -193.99% | -171.60% |
| Earnings from Discontinued Operations | 100.00% | 100.00% | 100.00% | 99.53% | 93.49% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.23% | -213.18% | -199.54% | -200.12% | -179.34% |
| EBIT | -49.32% | -84.15% | -59.63% | -23.14% | -21.58% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 20.01% | -179.27% | -176.31% | -253.66% | -244.37% |
| Normalized Basic EPS | 13.67% | -22.94% | -17.14% | 5.71% | -9.92% |
| EPS Diluted | 20.01% | -180.62% | -177.55% | -258.72% | -300.68% |
| Normalized Diluted EPS | 13.67% | -23.19% | -17.39% | 5.55% | -10.13% |
| Average Basic Shares Outstanding | 58.75% | 45.30% | 31.40% | 20.44% | 8.43% |
| Average Diluted Shares Outstanding | 58.75% | 44.91% | 31.05% | 20.10% | 8.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |